These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25938778

  • 21. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF, VA NEPHRON-D Study Group.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2159-69. PubMed ID: 26482258
    [Abstract] [Full Text] [Related]

  • 22. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL, Odum LE, Whaley-Connell AT.
    Pharmacotherapy; 2013 May 07; 33(5):496-514. PubMed ID: 23576066
    [Abstract] [Full Text] [Related]

  • 23. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.
    Lancet Diabetes Endocrinol; 2016 Apr 07; 4(4):309-17. PubMed ID: 26774608
    [Abstract] [Full Text] [Related]

  • 24. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P.
    Diabet Med; 2012 Aug 07; 29(8):e184-90. PubMed ID: 22268920
    [Abstract] [Full Text] [Related]

  • 25. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J.
    Am J Kidney Dis; 2007 Dec 07; 50(6):946-51. PubMed ID: 18037095
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial.
    Wu JJ, Zhang TY, Qi YH, Zhu MY, Fang Y, Qi CJ, Cao LO, Lu JF, Lu BH, Tang LM, Shen JX, Mou S.
    J Integr Med; 2024 May 07; 22(3):279-285. PubMed ID: 38688809
    [Abstract] [Full Text] [Related]

  • 27. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Hsu FY, Lin FJ, Ou HT, Huang SH, Wang CC.
    Kidney Blood Press Res; 2017 May 07; 42(2):358-368. PubMed ID: 28618426
    [Abstract] [Full Text] [Related]

  • 28. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
    Taheri S, Asim M, Al Malki H, Fituri O, Suthanthiran M, August P, IDEAL-2 Study Team.
    Trials; 2018 Apr 17; 19(1):230. PubMed ID: 29665833
    [Abstract] [Full Text] [Related]

  • 29. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P, PRIORITY investigators.
    Lancet Diabetes Endocrinol; 2020 Apr 17; 8(4):301-312. PubMed ID: 32135136
    [Abstract] [Full Text] [Related]

  • 30. Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
    He D, Zhang Y, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S.
    Horm Metab Res; 2020 May 17; 52(5):289-297. PubMed ID: 32219798
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness of the Shenzhuo formula in the treatment of patients with macroalbuminuria secondary to diabetic kidney disease: protocol update and statistical analysis plan.
    Wei Y, Huang YS, Yang Z, Wang X, Li Y, Zhang Y, Zhao LH, Tong X.
    Trials; 2022 Jan 20; 23(1):61. PubMed ID: 35057843
    [Abstract] [Full Text] [Related]

  • 32. [Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
    Guo ZA, Yu CJ, Liu G, Meng FC, Li Y, Peng SL.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep 20; 34(9):1047-52. PubMed ID: 25335326
    [Abstract] [Full Text] [Related]

  • 33. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov 20; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 34. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Zhang L, Yang L, Shergis J, Zhang L, Zhang AL, Guo X, Qin X, Johnson D, Liu X, Lu C, Xue CC, Mao W.
    BMJ Open; 2019 May 01; 9(4):e025653. PubMed ID: 31048437
    [Abstract] [Full Text] [Related]

  • 35. Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.
    Voroneanu L, Siriopol D, Dumea R, Badarau S, Kanbay M, Afsar B, Gavrilovici C, Covic A.
    Int Urol Nephrol; 2017 Dec 01; 49(12):2195-2204. PubMed ID: 28948420
    [Abstract] [Full Text] [Related]

  • 36. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial.
    Li N, Zhao W, Xing J, Liu J, Zhang G, Zhang Y, Li Y, Liu W, Shi F, Bai Y.
    BMC Complement Altern Med; 2017 May 15; 17(1):264. PubMed ID: 28506228
    [Abstract] [Full Text] [Related]

  • 37. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F, Tang L, Cai Y, Yuan X, Huang W, Luo L, Zhou J, Zheng Y.
    Ren Fail; 2015 May 15; 37(4):548-61. PubMed ID: 25707526
    [Abstract] [Full Text] [Related]

  • 38. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 39. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W, Qian X, Guo F, Zhang M, Lyu C, Tao J, Gao Z, Zhou Z.
    Chin Med J (Engl); 2014 Oct 20; 127(15):2721-6. PubMed ID: 25146603
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.